Tale of Two Cities: The Adalimumab Biosimilars Experience for Uveitis and Ocular Inflammatory Diseases at Two Texas Academic Centers
PBM-driven formulary changes disrupted treatment continuity for patients with non-infectious ocular inflammation. Enforcement of NMS mandates varied by PBM and often disregarded clinical stability and physician input, underscoring the urgent need for policy reform and uveitis-specific biosimilar outcome data.
Authors
- Jared Moon (ORCID: https://orcid.org/0000-0003-4728-4410)
- Karen Beltran
- Eric L. Crowell (ORCID: https://orcid.org/0000-0002-6986-5307)
- Jiafu Ji (ORCID: https://orcid.org/0000-0001-6878-5543)
- Jennifer Cao (ORCID: https://orcid.org/0000-0001-6129-9542)
Institutions
- Southwestern Medical Center (US)
- The University of Texas at Austin (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1080/09273948.2025.2566322
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00